相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis
Alireza Minagar et al.
ARCHIVES OF NEUROLOGY (2008)
Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis
Q.-X. Sang et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Differential expression of tissue inhibitor of metalloproteinases-3 in cultured astrocytes and neurons regulates the activation of matrix metalloproteinase-2
Wenlan Liu et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2007)
Matrix metalloproteinase-9 and autoimmune diseases
Maya Ram et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2006)
Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis
W Brück
JOURNAL OF NEUROLOGY (2005)
Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells
M Abraham et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
RHSR Roxburgh et al.
NEUROLOGY (2005)
Predicting the course of relapsing-remitting MS using longitudinal disability curves
A Achiron
JOURNAL OF NEUROLOGY (2004)
Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment
GM Liuzzi et al.
MULTIPLE SCLEROSIS (2004)
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis
A Bar-Or et al.
BRAIN (2003)
Interferon-β-1b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis
M Yushchenko et al.
JOURNAL OF NEUROLOGY (2003)
TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metal loproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP
MM Bernardo et al.
BIOCHEMICAL JOURNAL (2003)
Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes
M Toth et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes
C Avolio et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS
E Waubant et al.
NEUROLOGY (2003)
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
T Kuhlmann et al.
BRAIN (2002)
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis
GM Liuzzi et al.
MULTIPLE SCLEROSIS (2002)
Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes
EM Muir et al.
MOLECULAR BRAIN RESEARCH (2002)
Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
DS Goodin et al.
NEUROLOGY (2002)
T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases
TA Newman et al.
BRAIN (2001)
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis
D Leppert et al.
BRAIN RESEARCH REVIEWS (2001)
Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients
Y Galboiz et al.
ANNALS OF NEUROLOGY (2001)
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis
RLP Lindberg et al.
BRAIN (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
分享论文
